UKRI – £30 million fund to advance life-changing cancer therapeutics
Innovate UK is launching a new £30 million fund to advance life-changing cancer therapeutics delivered through the Biomedical Catalyst (BMC) programme.
This initiative aims to unleash business-led innovation from the UK’s vibrant research base in immuno-oncology, treatments that guide the patient’s own immune system to target their cancer cells.
In addition, this fund will support innovation projects that address unmet medical needs in treating childhood cancers, a leading cause of death between the ages of 0 to 14 in the UK.
Read the entire news report here. Published on the 28th of November 2022.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (25 janvier 2023). UKRI – £30 million fund to advance life-changing cancer therapeutics. ELSIBI. Consulté le 19 janvier 2026 à l’adresse https://doi.org/10.58079/o66v





